NCT04694989View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 20, 2021

Primary Completion Date

April 7, 2021

Study Completion Date

May 4, 2021

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-386

QD, PO

DRUG

D013, D326, D337

QD, PO

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04694989 - A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) | Biotech Hunter | Biotech Hunter